Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc. T.ONC

Alternate Symbol(s):  ONCWF | ONCY

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The company's product pipeline includes Bavencio, Keytruda, Retifanlimab, and Tecentriq.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:RE:.... when the news come......oh, my

Okee DoKeee, the news is out. Now what?   rate and reply
@ the Bell: Energy & mining recover to lift TSX
Following a nasty session in the red, Canada’s main stock index rose more than 300 points in Friday trading. Gains were led by the energy and base metal sectors.After two brutal weeks brought... read article.

RE:RE:Bracelet Fully Enrolled

https://twitter.com/prECOGonc  rate and reply

RE:Bracelet Fully Enrolled

The tweet link didn't included, here is the text PrECOG   ...read more

Bracelet Fully Enrolled

Final patient enrolled  rate and reply

RE:ONCY's reovirus/pelareorep + CAR-T in brain metastasis

The tweet appearing in the previous post was made by Dr. Bryan Choi, a Boston/Harvard neurologist and neuroscientist affiliated with the Massachusettes General Hospital in Boston. The Mayo Clinic...read more

RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff

June 24, 2022 - The pharmaceutical and life sciences industry is poised for a “flurry of deals” in the second half, according to PwC.   In a new report covering the first half of...read more

ONCY's reovirus/pelareorep + CAR-T in brain metastasis

  rate and reply
The Cannabis Report: June 24, 2022
Nextleaf to launch THC-O as an excise tax-free alternative to Delta-9-THC Nextleaf Solutions (OILS) has provided an update on the manufacturing of D9-tetrahydrocannabinol acetate,... read article.

RE:RE:.... when the news come......oh, my

Are you my accountant now? What else do I have? Tell us.  and what did you do to S er N err L aka NOTable? He run my inventory and accounts like a well oiled  AI. I will miss him. Nuts...read more

RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff

June 2022 - A patent cliff is looming once again for the biopharma industry, putting some $236 billion in pharmaceutical sales at risk between now and 2030.  Take-aways: Companies won’t...read more

RE:.... when the news come......oh, my

You must have a depressing life being so negative.  rate and reply

.... when the news come......oh, my

Oh My Goodness, wagon full of fools. Going for a treatment, eh? Did everybody get their pain meds? The lube? The feathers? Almost forgot, the whips, The crocodile jaw, your favorite. Oh, Nellie!!!!!  rate and reply

RE:RE:RE:Seems that sentiment is way better since a couple of weeks.

They'll be buying big time when the news comes out, and it will!  rate and reply

RE:RE:RE:Seems that sentiment is way better since a couple of weeks.

Now Mr. Parsons has 45k options at 1.14.  rate and reply

RE:RE:Seems that sentiment is way better since a couple of weeks.

it's not that no one is selling , it's more no one is buying is where we stand right now....  rate and reply

RE:Seems that sentiment is way better since a couple of weeks.

Add to that- the volume is pathetic. No one is selling.  rate and reply
Buzz on the Bullboards: Another summer of uncertainty?
In times of uncertainty in the markets, investors tend to focus on more consistent plays.Not all investors are basking in summer vacations and backyard barbeques. For those who are still plugged... read article.

Seems that sentiment is way better since a couple of weeks.

New director, insiders buying, insiders loaded with cheap options. The only missing piece is a significant NR. Fingers crossed for the coming weeks. GL  rate and reply

RE:RE:Big Pharma is facing a looming $236 Billion patent cliff

IBB: M&As Are Back Jun. 21, 2022 4:56 AM ETiShares Nasdaq Biotechnology ETF (IBB)CRSP, PFE, VRTX1 Like Summary Biotech stocks have had a terrible year so far...read more

RE:Big Pharma is facing a looming $236 Billion patent cliff

According to the 32nd edition of the Beyond Borders report produced by Ernst & Young LLP (EY US) contributor Arda Ural, PhD, EY Americas industry markets leader, health sciences and...read more

For Notable

Recent Dr. VILE tweet. " Several cancers share antigens that could be targets across treatments. Also run the risk of reacting with normal tissues." -----------------------------------------...read more

RE:Merck USA rumored to possibly acquire Seagen

Merck had formed a partnership with Seagen through an exclusive license to commercialize Seagen's Tukysa in several regions outside the U.S. and Canada. Seagen, formerly Seattle Genetics, received...read more